Syntarga Overview

  • Founded
  • 2002
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Syntarga General Information


Developer of cell-killing drugs, releasable linker technologies and linker-drug combinations for conjugation to tumor-specific antibodies and mAb derivatives. The company focuses its activities on the development of antibody payload chemistries, which, in combination with a third party antibody, yield Antibody-Drug Conjugate (ADC) products.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Delivery
Primary Office
  • Toernooiveld 1
  • 6525 ED Nijmegen
  • Netherlands
+31 024 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Syntarga Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 23-Jun-2011 Completed Generating Revenue
2. Later Stage VC 28-Nov-2010 Completed Generating Revenue
1. Early Stage VC (Series A) 20-Apr-2005 Completed Product Development
To view Syntarga’s complete valuation and funding history, request access »

Syntarga Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aglaia Oncology Funds Venture Capital Minority 000 0000 000000 0
BioPartner Start-up Ventures Not-For-Profit Venture Capital Minority 000 0000 000000 0
Oost NL Venture Capital Minority 000 0000 000000 0
Radboud University Endowment Limited Partner Minority 000 0000 000000 0
To view Syntarga’s complete investors history, request access »